Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19

Not Applicable

Completed

• Conditions: Vaccine Refusal; Covid19
• Interventions: Behavioral: Messaging informed by construal level theory; Behavioral: Usual Care

• Registration Number: NCT04871776
• Lead Sponsor: Brigham and Women's Hospital

Brief Summary

This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-04-30
• Study First Submitted QC: 2021-04-30
• Study First Posted: 2021-05-04
• Study Start: 2022-02-18
• Primary Completion: 2022-05-27
• Study Completion: 2022-08-17
• Results First Submitted: 2023-05-05
• Status Verified: 2023-12
• Results First Submitted QC: 2023-12-22
• Last Update Submitted: 2023-12-22
• Results First Posted: 2024-01-16
• Last Update Posted: 2024-01-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3671

Inclusion Criteria

• Patients in the Mass General Brigham system
• Aged 18 and older
• Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit

Exclusion Criteria

• Documented allergy to a COVID vaccine or its components
• Home address outside of Massachusetts
• Did not receive full set of primary COVID-19 vaccination series

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
"Why" messaging	Messaging informed by construal level theory	In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. Messages will focus on reasons to get the COVID booster vaccine, including protecting self and loved ones or the idea of herd immunity.
"How" messaging	Messaging informed by construal level theory	In this arm, patients will be sent an electronic patient portal message a few days in advance of their office visit. "How" messages will focus on the details of obtaining a vaccination at MGB, what to expect, and how to prepare for the visit.
Usual Care	Usual Care	In this arm, patients will not receive any additional message about their upcoming visit, beyond what they already receive by the health system.

Primary Outcome Measures

Name	Time	Method
Number of Participants Who Received a Booster Vaccination Through the Targeted Visit	2-5 days	Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.

Secondary Outcome Measures

Name	Time	Method
Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit	6 weeks after the target visit	Number of participants who received one dose of a COVID booster vaccine between randomization through 6 weeks after the targeted visit, determined through electronic health records.

Trial Locations

Locations (1)

Mass General Brigham; 🇺🇸 Boston, Massachusetts, United States